Neos Therapeutics

Neos Therapeutics develops, manufactures, and commercializes branded products using our proprietary, extended-release drug delivery technology platform. We have used this technology to develop products for the treatment of attention deficit hyperactivity disorder (ADHD), including an extended-release orally disintegrating tablet. We are also using this technology to develop two additional product candidates: Oral disintegrating tablets (ODT) Oral suspension dosage forms.
Company Growth (employees)
Type
Public
HQ
Grand Prairie, US
Founded
2008
Size (employees)
81 (est)
Website
neostx.com
Neos Therapeutics was founded in 2008 and is headquartered in Grand Prairie, US

Key People at Neos Therapeutics

Vipin Garg

Vipin Garg

CEO
Richard Eisenstadt

Richard Eisenstadt

CFO
Russ McMahen

Russ McMahen

Executive Vice President of Operations and Vice President of Scientific Affairs
Dorothy Engelking

Dorothy Engelking

VP of Regulatory Affairs
Margaret Cabano

Margaret Cabano

VP of Operations

Neos Therapeutics Office Locations

Neos Therapeutics has offices in Grand Prairie and Blue Bell
Grand Prairie, US (HQ)
2940 N. Highway 360
Blue Bell, US
130 1787 Sentry Pkwy W

Neos Therapeutics Data and Metrics

Neos Therapeutics Financial Metrics

Neos Therapeutics's revenue was reported to be $9.2 m in FY, 2016 which is a 141% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

9.2 m

Revenue growth (FY, 2015 - FY, 2016), %

141%

Gross profit (FY, 2016)

(2.3 m)

Gross profit margin (FY, 2016), %

(25%)

Net income (FY, 2016)

(83.3 m)

EBIT (FY, 2016)

(76.4 m)

Market capitalization (26-May-2017)

185 m

Closing share price (26-May-2017)

8.3

Cash (31-Dec-2016)

24.4 m

EV

224.2 m
Neos Therapeutics's current market capitalization is $185 m.
Numbers are in $, USDFY, 2015FY, 2016

Revenue

3.8 m9.2 m

Revenue growth, %

141%

Cost of goods sold

5.5 m11.4 m

Gross profit

(1.8 m)(2.3 m)

Gross profit Margin, %

(46%)(25%)

R&D expense

11.9 m12.2 m

General and administrative expense

7.5 m12.6 m

Operating expense total

19.4 m24.8 m

EBIT

(26.6 m)(76.4 m)

EBIT margin, %

(701%)(835%)

Interest expense

(3.7 m)(6.9 m)

Net Income

(30.8 m)(83.3 m)
Numbers are in $, USDFY, 2015FY, 2016

Cash

90.8 m24.4 m

Inventories

2.5 m5.8 m

Current Assets

98.2 m55.3 m

PP&E

5.1 m7.1 m

Total Assets

122.5 m80.1 m

Accounts Payable

4.8 m7.8 m

Total Debt

34.2 m63.5 m

Current Liabilities

15.9 m21.6 m

Non-Current Liabilities

28.2 m60 m

Total Liabilities

44.1 m81.7 m

Additional Paid-in Capital

195.3 m198.8 m

Retained Earnings

(116.8 m)(200.1 m)

Total Equity

78.4 m(1.5 m)

Debt to Equity Ratio

0.4 x-41 x

Debt to Assets Ratio

0.3 x0.8 x

Financial Leverage

1.6 x-51.8 x
Numbers are in $, USDFY, 2015FY, 2016

Net Income

(30.8 m)(83.3 m)

Accounts Receivable

(2.2 m)

Inventories

2.5 m(3.2 m)

Accounts Payable

4.8 m3 m

Cash From Operating Activities

(70.6 m)

Capital Expenditures

(3.6 m)

Cash From Investing Activities

(19.3 m)

Cash From Financing Activities

23.6 m

Interest Paid

2.9 m

Free Cash Flow

(74.2 m)
Numbers are in $, USDY, 2016

EV/EBIT

-2.9 x

EV/CFO

-3.2 x

EV/FCF

-3 x

Revenue/Employee

113 k

Debt/Equity

-41 x

Debt/Assets

0.8 x

Financial Leverage

-51.8 x

Neos Therapeutics Market Value History

Neos Therapeutics News and Updates

Neos Therapeutics Company Life and Culture

You may also be interested in